Allogene Therapeutics, Inc. OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax
Allogene Therapeutics, Inc. (ALLO) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax of -$7.36 million for the 12-month period ending 2022-12-31, per its 10-K/A filed 2024-03-14.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax · last filed 2024-03-14
- Allogene Therapeutics, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2022 was -$7.36M.
- Allogene Therapeutics, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2021 was -$2.83M.
- Allogene Therapeutics, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2020 was -$877.00K.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 12 month |
|---|---|
| 2022-12-31 | -$7.36M 10-K/A · filed 2024-03-14 |
| 2021-12-31 | -$2.83M 10-K/A · filed 2024-03-14 |
| 2020-12-31 | -$877.00K 10-K/A · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |